May 6-11, 2018
Lentiviral vectors (LVs) are becoming an important tool in gene and cell therapy and are being utilized in several clinical studies against genetic and acquired diseases, as well as in cancer therapies. To address the challenges linked to the generation of preclinical and clinical supply, the National Research Council Canada has developed packaging cell lines and stable producer cell lines for the production of LVs which can grow in suspension in serum-free media and produce LV in the 106 TU/ml range without optimization. We focus on the development of perfusion processes to both intensify the process and harvest produced LV rapidly.
Sven Ansorge, Aziza Manceur, Stéphane Lanthier, Sonia Tremblay, Anne-Marie Gélinas, July Dorion-Thibaudeau, Sophie Broussau, Julia Transfiguracion, Hafida Aomari, and Rénald Gilbert, "Scalable lentiviral vector production using stable producer cell lines in perfusion mode" in "Cell Culture Engineering XVI", A. Robinson, PhD, Tulane University R. Venkat, PhD, MedImmune E. Schaefer, ScD, J&J Janssen Eds, ECI Symposium Series, (2018). http://dc.engconfintl.org/ccexvi/61